217 related articles for article (PubMed ID: 21205756)
21. Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance.
Zhu YM; Wang PP; Huang JY; Chen YS; Chen B; Dai YJ; Yan H; Hu Y; Cheng WY; Ma TT; Chen SJ; Shen Y
J Transl Med; 2017 Aug; 15(1):178. PubMed ID: 28830460
[TBL] [Abstract][Full Text] [Related]
22. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.
Ribeiro AF; Pratcorona M; Erpelinck-Verschueren C; Rockova V; Sanders M; Abbas S; Figueroa ME; Zeilemaker A; Melnick A; Löwenberg B; Valk PJ; Delwel R
Blood; 2012 Jun; 119(24):5824-31. PubMed ID: 22490330
[TBL] [Abstract][Full Text] [Related]
23. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics.
Heuser M; Beutel G; Krauter J; Döhner K; von Neuhoff N; Schlegelberger B; Ganser A
Blood; 2006 Dec; 108(12):3898-905. PubMed ID: 16912223
[TBL] [Abstract][Full Text] [Related]
24. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
Dufour A; Schneider F; Hoster E; Benthaus T; Ksienzyk B; Schneider S; Kakadia PM; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Subklewe M; Hiddemann W; Bohlander SK; Spiekermann K;
Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118
[TBL] [Abstract][Full Text] [Related]
25. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia.
Santamaría CM; Chillón MC; García-Sanz R; Pérez C; Caballero MD; Ramos F; de Coca AG; Alonso JM; Giraldo P; Bernal T; Queizán JA; Rodriguez JN; Fernández-Abellán P; Bárez A; Peñarrubia MJ; Balanzategui A; Vidriales MB; Sarasquete ME; Alcoceba M; Díaz-Mediavilla J; San Miguel JF; Gonzalez M
Blood; 2009 Jul; 114(1):148-52. PubMed ID: 19398719
[TBL] [Abstract][Full Text] [Related]
26. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.
Marcucci G; Baldus CD; Ruppert AS; Radmacher MD; Mrózek K; Whitman SP; Kolitz JE; Edwards CG; Vardiman JW; Powell BL; Baer MR; Moore JO; Perrotti D; Caligiuri MA; Carroll AJ; Larson RA; de la Chapelle A; Bloomfield CD
J Clin Oncol; 2005 Dec; 23(36):9234-42. PubMed ID: 16275934
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
Thol F; Yun H; Sonntag AK; Damm F; Weissinger EM; Krauter J; Wagner K; Morgan M; Wichmann M; Göhring G; Bug G; Ottmann O; Hofmann WK; Schambach A; Schlegelberger B; Haferlach T; Bowen D; Mills K; Ganser A; Heuser M
Ann Hematol; 2012 Aug; 91(8):1221-33. PubMed ID: 22488406
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
Port M; Böttcher M; Thol F; Ganser A; Schlenk R; Wasem J; Neumann A; Pouryamout L
Ann Hematol; 2014 Aug; 93(8):1279-86. PubMed ID: 24801015
[TBL] [Abstract][Full Text] [Related]
30. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
[TBL] [Abstract][Full Text] [Related]
31. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
32. BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
Zhang J; Shi J; Zhang G; Zhang X; Yang X; Yang S; Wang J; Ke X; Fu L
Ann Hematol; 2018 Aug; 97(8):1391-1397. PubMed ID: 29696374
[TBL] [Abstract][Full Text] [Related]
33. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications.
Thol F; Bollin R; Gehlhaar M; Walter C; Dugas M; Suchanek KJ; Kirchner A; Huang L; Chaturvedi A; Wichmann M; Wiehlmann L; Shahswar R; Damm F; Göhring G; Schlegelberger B; Schlenk R; Döhner K; Döhner H; Krauter J; Ganser A; Heuser M
Blood; 2014 Feb; 123(6):914-20. PubMed ID: 24335498
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia.
Tian Y; Huang Z; Wang Z; Yin C; Zhou L; Zhang L; Huang K; Zhou H; Jiang X; Li J; Liao L; Yang M; Meng F
PLoS One; 2014; 9(1):e84150. PubMed ID: 24416201
[TBL] [Abstract][Full Text] [Related]
35. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
36.
Bai H; Zhou M; Zeng M; Han L
DNA Cell Biol; 2020 Apr; 39(4):700-708. PubMed ID: 32077754
[TBL] [Abstract][Full Text] [Related]
37. NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.
Chretien AS; Fauriat C; Orlanducci F; Rey J; Borg GB; Gautherot E; Granjeaud S; Demerle C; Hamel JF; Cerwenka A; von Strandmann EP; Ifrah N; Lacombe C; Cornillet-Lefebvre P; Delaunay J; Toubert A; Arnoulet C; Vey N; Olive D
Oncotarget; 2017 Jul; 8(30):49548-49563. PubMed ID: 28548938
[TBL] [Abstract][Full Text] [Related]
38. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
[TBL] [Abstract][Full Text] [Related]
39. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.
Kuwatsuka Y; Tomizawa D; Kihara R; Nagata Y; Shiba N; Iijima-Yamashita Y; Shimada A; Deguchi T; Miyachi H; Tawa A; Taga T; Kinoshita A; Nakayama H; Kiyokawa N; Saito AM; Koh K; Goto H; Kosaka Y; Asou N; Ohtake S; Miyawaki S; Miyazaki Y; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kobayashi S; Kitamura K; Sakaida E; Ogawa S; Naoe T; Hayashi Y; Horibe K; Manabe A; Mizutani S; Adachi S; Kiyoi H
Int J Hematol; 2018 Feb; 107(2):201-210. PubMed ID: 29027108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
